NorthView Acquisition Corp - Tradeable Rights - Aug 2027
NVACR
Get informed when a big investor buys or sells
+ FollowMarket Cap$78.44M
Close$
Share Statistics
| Market cap | $78.44 Million |
|---|---|
| Enterprise Value | $91.84 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-107.01 |
| Beta | 0.02 |
| Outstanding Shares | 1,688,107 |
Return
| Return on Equity | 135.33% |
|---|---|
| Return on Assets | -4426.81% |
| Return on Invested Capital | 110.55% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | -0.01 |
| Price to Sales | - |
| Price to Book Ratio | -0.01 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.95 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | -0.49 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 30.40%▲ 3.65% |
|---|---|
| Total Invested | $38,000▲ 31.03% |
| Investors Holding | 10% |
ESG Score
No data
About Profusa, Inc. Common Stock
2 employees
CEO: Ben Chung-Bin Hwang A digital-health company developing tissue-integrating biosensors (e.g. the Lumee™ Oxygen Platform) to continuously monitor body chemistry and provide AI-powered health insights, targeting chronic conditions such as diabetes and critical limb ischemia